According to a meta-analysis of human intervention studies, diets that consist of low glycaemic index foods have significant health benefits when compared to diets high in rapidly absorbable sugars( Reference Livesey, Taylor and Hulshof 1 ), while high glycaemic index carbohydrates in developed nations have contributed to the epidemics of obesity and cardiometabolic disease( Reference Ludwig, Hu and Tappy 2 ). The glycaemic index of foods is affected by many factors, but certain natural compounds present may reduce the rate of sugar digestion and absorption and hence modify the glycaemic index, even in foods with comparable amounts of carbohydrate. In fact, this notion was first suggested for polyphenols more than 30 years ago( Reference Jenkins, Wolever and Taylor 3 ), but has received more attention only recently, owing to the increased threat of developing diabetes in a high proportion of the global population( Reference Marsh, Barclay and Colagiuri 4 ). The appearance of postprandial glucose in the blood is accompanied by mobilisation of hormones such as insulin which assist extra-hepatic tissues in taking up the excess glucose. Previous research has suggested that the glycaemic response can be attenuated by several polyphenol-rich foods, such as coffee( Reference Johnston, Clifford and Morgan 5 ), green tea( Reference Tsuneki, Ishizuka and Terasawa 6 ), berries( Reference Torronen, Kolehmainen and Sarkkinen 7 ) and pomegranate juice( Reference Kerimi, Nyambe-Silavwe and Gauer 8 ). The mechanism may be partly through inhibition of digestive enzymes such as α-amylase, as clinically exemplified by acarbose( Reference Shimabukuro, Higa and Chinen 9 ), but also by delaying glucose transport across the intestinal barrier. The latter has been supported by studies in rats where naringenin, the aglycone of narirutin from orange juice, inhibited glucose transport across the intestine( Reference Li, Che and Lau 10 ) and in vitro where polyphenols from strawberries( Reference Manzano and Williamson 11 ), apples( Reference Manzano and Williamson 11 ), pomegranate( Reference Kerimi, Nyambe-Silavwe and Gauer 8 ), olives( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ) and chamomile( Reference Villa-Rodriguez, Aydin and Gauer 13 ) attenuated the transport of glucose across an intestinal Caco-2 cell monolayer as a model of the small intestine. Orange juice contains glucose, sucrose and fructose but has a lower glycaemic index than expected (50 (sd 4) relative to glucose) when compared to many foods with comparable levels of sugars( Reference Foster-Powell, Holt and Brand-Miller 14 ). Both oranges and orange juice are very high in the polyphenol hesperidin (Fig. 1), a flavanone that consists of hesperetin linked to glucose and rhamnose moieties( Reference Neveu, Perez-Jimenez and Vos 15 ). We tested whether the presence of hesperidin could attenuate the glycaemic response of orange juice employing a combination of in vitro mechanistic studies and interventions in healthy volunteers.
Methods
Materials
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. Magnesium sulphate was from VWR International. Transwell plates with polycarbonate inserts (6 well, 0·4 µm pore size), tissue culture flasks and filter system (500 ml, 0·2 µm nylon membrane) were from Corning (Appleton Woods). d-[14C(U)]-glucose was from Perkin Elmer, d-[14C(U)]-fructose was from Hartmann Analytic, and d-fructose, d-glucose and Glutamax were from Thermo Fisher Scientific. Gold Star scintillation cocktail was from Meridian Biotechnologies. Concentrated frozen orange juice (4× concentrate) was from Florida Department of Citrus, USA, and termed orange juice 1. Princes long life 100 % smooth orange juice was from Costco and termed orange juice 2. Hesperidin (micronised 2S hesperidin) used in the intervention studies was from Ferrer HealthTech (www.ferrer.com/ferrer-healthtech). For the intervention study, glucose and fructose were from Holland & Barrett, sucrose was from Tate and Lyle from a local supermarket, citric acid was from Minerals-Water, malic acid was from Bartek Ingredients Inc., and ascorbic acid was from NutriBiotic. Sodium bicarbonate, used to adjust the pH of the control solution to the same pH as the orange juice, was from HealthLeads (healthleadsuk.com).
Preparation of orange juice and its constituents for in vitro experiments
Orange juice from concentrate (stored in frozen form) was centrifuged (2400 g , 30 min) and one part from the supernatant was diluted with Milli-Q water (to make regular strength orange juice). The pH was adjusted to 7·4 by the addition of NaOH 1 m and the final dilution of orange juice and water was 1:3. For tests with 10-fold diluted samples, the regular strength orange juice was further diluted with transport buffer (HEPES, 20 mm; NaCl, 137 mm; KCl, 4·7 mm; CaCl2, 1·8 mm and MgSO4, 1·2 mm; adjusted to pH 7·4 using NaOH, 1 m) and the pH re-adjusted to 7·4. Glucose, fructose and sucrose were dissolved directly in transport buffer. Stock solutions of hesperidin were prepared in dimethyl sulfoxide (DMSO) and added to the transport buffer containing sugars or to the ‘regular strength’ orange juice and used immediately or after further dilution. The final concentration of DMSO in transport buffer was 0·1 %.
Analysis of orange juice and its constituents
The analysis of the juice given to volunteers is shown in Table 1 (‘orange juice 2’). It is different to that used for the in vitro studies (‘orange juice 1’). Analysis of sugars( Reference White and Cancalon 16 ) and hesperidin( 17 ) in ‘orange juice 1’ was performed by HPLC, and analysis of ascorbic acid, dehydroascorbic acid and citric acid were performed by capillary electrophoresis( Reference Cancalon 18 ). Ascorbic acid content of ‘orange juice 2’ was determined by titration with 2,6-dichlorophenol indophenol against a standard curve of ascorbic acid. Malic, citric acid and sugars were analysed as previously described( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ).
ND, not determined.
The content of hesperidin in ‘orange juice 2’ and in solubility studies was determined by HPLC on an Agilent 1200 series system (Agilent Technologies). Samples were filtered using 0·45 and 0·2 µm pore size syringe filters and 5 µl were injected on a ZORBAX Eclipse Plus C18 column (2·1×11 mm) and maintained at 30°C, at a flow rate of 0·3 ml/min. The solvents used were Milli-Q water/formic acid (95:5; v/v, mobile phase A) and acetonitrile–Milli-Q water–formic acid (90:9:1; v/v, mobile phase B). Separation was achieved by a gradient starting at 5 % B, reaching 95 % B at 20 min, kept at 95 % B for 10 min before returning to baseline. Triplicate analyses were performed for each sample and the absorbance was monitored at 260, 280, 320 and 360 nm. A standard curve was run between 0·005 and 0·1 mm hesperidin with r 2 0·999 and retention time of 8·34 (sd 0·03) min (n 44). Orange juice samples were diluted with water as appropriate to fit the hesperidin concentration onto the standard curve (typically 1:10). To test solubility, hesperidin dissolved in DMSO (490 mg in 0·5 ml) was added to ‘orange juice 2’ (final concentration of 490 mg hesperidin/l, that is, an additional 0·80 mm). The concentration of hesperidin was measured by HPLC and was 0·987 (sd 0·032) mm (predicted value 0·968 mm, if 100 % hesperidin was in solution after DMSO addition). This shows that hesperidin in DMSO when added to orange juice for in vitro experiments is apparently soluble as assessed by centrifugation, at least up to 0·8 mm.
Culture of Caco-2/TC7 cell monolayers for sugar transport studies
Caco-2/TC7 cells( Reference Zucco, Batto and Bises 19 ) were kindly provided by Dr M. Rousset (INSERM, U170). Cells (1·2×106) were seeded on 75 cm2 cell culture flasks and maintained as described before( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ). For glucose transport studies, cells were seeded on 6- or 12-well transwell plates at a density of 6×104 cells/cm2. The cells were allowed to grow and differentiate up to 22 d in complete medium in the apical and basolateral side, while the apical side was deprived of fetal bovine serum after 7 d.
Measurements of glucose and fructose transport across Caco-2/TC7 cell monolayers
Differentiated Caco-2/TC7 cell monolayers were used to study the effect of orange juice on glucose transport, from the apical to the basolateral side. On or after 22 d, permeability studies were initiated by careful aspiration of the culture medium from apical and basal compartments, and transport buffer A (HEPES, 20 mm; NaCl, 137 mm; KCl, 4·7 mm; CaCl2, 1·8 mm and MgSO4, 1·2 mm; adjusted to pH 7·4 using NaOH, 1 m) was added to each compartment to carefully wash cells. After washing, the solutions were removed and fresh transport buffer A was added into each compartment. Dishes were incubated at 37°C (10 % CO2) for 30 min to allow equilibration of tight junction integrity. Transepithelial electrical resistance measurements were recorded using a Millicell ERS volt-ohm meter fitted with a chopstick probe (Millipore Ltd). The liquid was aspirated and the relevant test solution at pH 7·4 was mixed with 0·1 µCi/ml d-[U-14C]-glucose or d-[U-14C]-fructose and added apically. All basal solutions consisted of transport buffer at pH 7·4. Plates were incubated for 30 min, and the solutions were removed. Apical and basal compartments were washed twice with transport buffer to remove any residual d-[U-14C] glucose or fructose from the cell monolayer or compartment walls and the aliquots were collected. Radiochemical detection of the d-[U-14C]-label was performed by combining 5 ml of scintillation cocktail with the apical solutions or the basal solutions and the apical and basal wash solutions. All samples were analysed using a Packard Liquid Scintillation Analyser 1600TR. An aliquot of each test solution was also used to construct an independent standard curve to assess the transport of glucose across to the basolateral side and corrected for any solution matrix effects on radioactive counting.
Inhibition of human GLUT2 and GLUT5 expressed in Xenopus laevis oocytes
Expression of transporters in Xenopus laevis oocytes and inhibition experiments were conducted as described previously( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ). Briefly, after microinjection with mRNA or water as control, oocytes were incubated in 100 µm 0·5 µCi/ml d-[14C(U)]-glucose (GLUT2) or d-[14C(U)]-fructose (GLUT2 and GLUT5). Incubations were for 5 min at 25°C. To terminate the incubation, oocytes (three per reaction) were washed with ice cold 100 µm sugar solution and homogenised in 0·3 m sucrose containing 10 mm sodium phosphate and a protease inhibitor mixture. After centrifugation at 48 000 g for 1 h at 4°C, supernatant was added to a vial containing 5 ml of scintillation fluid and radioactivity was measured using a Packard Tri-Carb 1900 TR Liquid Scintillation Counter.
Assay for sucrase activity
Inhibition of rat sucrase activity was carried out using a rat intestinal protein extract with sucrose as substrate as described previously( Reference Pyner, Nyambe-Silavwe and Williamson 20 ). Briefly, the assay consisted of substrate (200 µl of sucrose), sodium phosphate buffer (50 µl, 10 mm), inhibitor or extra buffer (50 µl), and the reaction started by adding 200 µl of acetone-derived protein extract of rat intestine (20 mg solid/ml). After incubation at 37°C for 20 min, the reaction was stopped by placing the tubes in a water bath at 100°C for 10 min, cooling to room temperature, polyphenols removed by solid phase extraction and the resulting solution analysed for glucose at 340 nm in a plate reader using hexokinase. Inhibition was calculated as a percentage of the control.
Intervention studies on healthy volunteers
All intervention studies were approved by the University of Leeds, Faculties of Mathematics and Physical Sciences and Engineering Ethics Committee and were registered at clinicaltrials.gov (NCT03522896). The three independent studies were conducted between September 2017 and May 2018 and are shown in Fig. 9. The suitability of participants was assessed using a pre-study questionnaire, with inclusion criteria as apparently healthy, aged between 18 and 75 years, not smoking, not diabetic, not pregnant, not lactating and not on long-term prescribed medication, with a fasting blood glucose of 3·9–5·9 mm. All participants provided written informed consent before the study started, and height and weight were recorded at the start of the study. Study beverages were given in a crossover design, in a semi-randomised order based on drawing lots (see below), and each volunteer attended twice for the control and twice for the treatment. Participants consumed their normal diet during the studies, but ate the same evening meal on the day before each visit. Participants were enrolled by J. L., J. W. C. and Ryan Kuipers, and the participants arrived at the School of Food Science and Nutrition, University of Leeds premises at approximately 09.00 hours after overnight fasting for at least 12 h. There were no restrictions on physical activity. Data were anonymised by assigning each participant a code. Study 1 involved orange juice 2 with added hesperidin (98 mg/200 ml portion). Study 2 involved orange juice 2 with additional hesperidin (37 mg/200 ml portion). Study 3 was 2-fold diluted orange juice 2 with added hesperidin (49 mg/200 ml portion). Table 2 gives the full details of the beverage compositions. Semi-randomisation in study 1 was performed for the first and second visits and then the third and fourth visits followed the same pattern. For studies 2 and 3, the first beverage was the test material, followed by the control or test in randomised order. Subjects were randomised where indicated by drawing the names of test materials from a ‘hat’. The ‘randomisation’ described is not truly random since the control was only available after the orange juice for studies 2 and 3, which dictated that the orange juice comprised the beverage for the first visit. Capillary blood samples were obtained by finger prick at 0 min (fasting blood glucose) using an Accu-Chek Aviva glucometer according to the FAO/WHO-approved method( Reference Brouns, Bjorck and Frayn 21 ), and the accuracy has been previously validated( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ). Following a finger prick, the second drop of blood was used for the measurement of glucose at the indicated time points (15, 30, 45, 60, 75, 90, 120, 150 and 180 min). The peak glucose concentration (C max) was used as the primary outcome, since the power calculation was based on this, and the incremental AUC (IAUC) was also estimated based on the same blood glucose data( Reference Wolever 22 ). Full details have been described previously( Reference Kerimi, Nyambe-Silavwe and Gauer 8 ). For each study listed, ten volunteers were recruited, and the details of control drinks and treatments are provided in Table 2. No side effects were reported during the study.
f, Females; m, males.
* All studies were crossover and controlled, with two visits per volunteer per treatment, and were conducted in parallel with different volunteers in each study.
† Drink 1 contained (all mm): glucose, 197; fructose, 138; sucrose, 151; citric acid, 2·7; malic acid, 1·04; ascorbic acid, 1·9. The treatment contained all of these components at the same concentration.
‡ Drink 2 contained (all mm) glucose, 98; fructose, 69; sucrose, 76; citric acid, 1·35; malic acid, 0·52; ascorbic acid, 0·95. The treatment contained all of these components at the same concentration.
Statistics and replicates
Sample size was determined by designing the trial to have 90 % power to detect a clinical difference of 20 % IAUC between test and reference meals based on a power calculation previously reported by us, with α=0·05 and β=0·1( Reference Nyambe-Silavwe and Williamson 23 ). The CV of peak glucose measurement was 11·9 % based on the calculation given in full in Nyambe( Reference Nyambe 24 ). With participants being controls of themselves, and each attending twice for each intervention, a minimum of ten participants was required, as calculated and used before( Reference Brouns, Bjorck and Frayn 21 ). The trapezoidal rule was used to calculate the IAUC for each volunteer, and data analysis was performed by the two-tailed paired t test. Comparisons between control and treatment in d-[U-14C]-glucose and [U-14C]-deoxy-d-glucose uptake cell experiments was carried out by independent samples two-tailed Student’s t test between control and treatment, and the two-tailed values were adjusted for multiple comparisons with the Bonferroni correction; data are presented as mean values and standard deviations with a minimum of three independent experiments and six replicate wells/experiment. For [14C(U)]-glucose and [14C(U)]-fructose uptake experiments into Xenopus oocytes expressing human GLUT2 and GLUT5, data were normalised against water-injected oocytes for each condition, and the two-tailed independent samples t test was used to assess significance, as reported previously( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ).
Results
Differentiated Caco-2/TC7 monolayers transport [14C(U)]-glucose from the apical to basolateral compartments and are a commonly used model to study the potential modulators of intestinal absorption of sugars. At 5 mm apical glucose, the rate of transport was 19·3 (sd 3·3) nmol/min, which equates to a transport of 13 % of the applied [14C(U)]-glucose over the incubation time of 30 min, comparable to our previous data using this system( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ). The composition of the orange juice tested in the cell experiments is shown in Table 1, and these values were used to design the transport experiments. Hesperidin alone exhibited significant inhibition when applied at the tested concentrations of 80 and 800 µm, typical concentrations found in orange juice (Table 1). However, the much higher concentration of 1600 µm did not show significant inhibition and even slightly enhanced transport (Fig. 2). Since the inhibition appeared more complex than a simple dose–response, and hesperidin in orange juice would normally be contained within the matrix of the juice affecting its solubility( Reference Gil-Izquierdo, Gil and Tomas-Barberan 25 ), we then tested the effects of orange juice, neutralised to the jejunal pH of 7·4, on the transport of [14C(U)]-glucose. However, the high glucose concentration of orange juice necessitated increasing the concentration of glucose in the apical compartment in the control experiments, and so to set up the system, we tested the transport of [14C(U)]-glucose at higher glucose concentrations. Under these conditions, [14C(U)]-glucose transport was enhanced by the presence of fructose and sucrose, when present at the same concentrations as in orange juice (Fig. 3). Under these conditions, hesperidin attenuated the transport of [14C(U)]-glucose. Adding extra hesperidin to orange juice did not markedly change the rate of transport of [14C(U)]-glucose (Fig. 3).
After consumption, beverages are diluted with digestive juices such as saliva, stomach secretions, pancreatic juice and small intestinal secretions before reaching the small intestine, but the exact amount of dilution is complex and dependent on many factors and this fact has been known for many years( Reference Hendrix and Bayless 26 ). We therefore tested the effects of a more substantially diluted orange juice (10-fold) on transport of [14C(U)]-glucose. All experiments on 10-fold diluted juice were compared to 12 mm glucose (the concentration in 10-fold diluted juice) together with 13 mm fructose and 13 mm sucrose. Added hesperidin, that is, both when added to the component sugars and to the juice itself, significantly inhibited the transport of [14C(U)]-glucose (Fig. 4). To determine the relative contribution of sodium-glucose linked transporter 1 (SGLT1) to the transport, Na-free conditions were compared with normal Na-containing transport buffer. The absence of Na led to an approximately 31 % (P<0·001) decrease in the transport of 14C-glucose, and the presence of 800 µm hesperidin further decreased this by approximately 38 %, P<0·001 (Fig. 5).
We also tested the effect of orange juice and hesperidin on transport of fructose across differentiated Caco-2 cell monolayers. Hesperidin mildly inhibited [14C(U)]-fructose transport from apical to basolateral compartments, but this inhibitory effect was abolished in the presence of other sugars (Fig. 6(a)). Consistent with this, hesperidin showed a greater inhibition at lower concentration of sugars (Fig. 6(b)). To examine the mechanisms further, we tested the effect of hesperidin on [14C(U)]-glucose transport into X. laevis oocytes expressing human GLUT2. Hesperidin inhibited GLUT2 but the effect was modest (Fig. 7(a)). On the other hand, the aglycone hesperetin was a much more potent inhibitor (Fig. 7(b)). In contrast, hesperidin was a more effective inhibitor of [14C(U)]-fructose transport by GLUT5 in comparison to hesperetin (Fig. 7(c) and (d)).
The sucrose component of any food or beverage requires prior hydrolysis by the brush border enzyme sucrase before absorption of the component sugars as glucose and fructose via sugar transporters( Reference Kishi, Tanaka and Igawa 27 ). To determine whether hesperidin could affect the digestive hydrolytic step, we determined its effect on rat sucrase activity. In contrast to acarbose, which as positive control was an excellent inhibitor, hesperidin even up to 1 mm did not inhibit sucrase activity (Fig. 8). We can therefore predict that any effects of hesperidin on postprandial glycaemia after orange juice consumption would be through inhibition of GLUT transporters and not attenuation of brush border sucrase activity.
To determine whether the effects observed in vitro on sugar transport were sufficient to elicit an effect in vivo, we conducted three separate human intervention studies on orange juice and measured the postprandial glycaemic response as biomarker for the effect of hesperidin. The analysis of the juice given to volunteers is shown in Table 1 (‘orange juice 2’). It is different to that used for the in vitro studies (‘orange juice 1’). This is due to Hurricane Irma (Florida, US, August 2017) which resulted in the loss of the stored orange juice at the Florida Department of Citrus, which had been used for the in vitro work, and consequently no further supplies for the intervention studies were available. We therefore used a different commercially available orange juice for consumption by volunteers.
Volunteers consumed orange juice supplemented with two different doses of hesperidin or diluted orange juice with added hesperidin according to the design shown in Table 2 and Fig. 9. The control drink contained glucose, fructose, sucrose, ascorbic acid, citric acid and malic acid at the same concentrations as found in the orange juice. The results are summarised in Fig. 10. The effect on postprandial glycaemia was most pronounced in the case of the diluted orange juice, where there was a highly significant decrease in the peak blood glucose relative to the control drink (ΔC max=–0·5 mm, P=0·0146). This decrease was seen in all individuals (Fig. 11), where the change in glucose C max can be clearly seen from 15 to 30 min. The change in peak blood glucose was also significant for one of the hesperidin-supplemented orange juices, although no significant change in AUC could be observed for all three studies.
Discussion
Consumption of hesperidin has been shown to affect several health biomarkers in studies on volunteers( Reference Homayouni, Haidari and Hedayati 28 – Reference Morand, Dubray and Milenkovic 31 ). It also attenuated hyperglycaemia in animal models, such as in male C57BL/KsJ-db/db mice, an animal model for type 2 diabetes( Reference Jung, Lee and Jeong 32 ). However, the effect of hesperidin on glucose absorption and carbohydrate digestion has not been explored. We therefore tested the hypothesis that hesperidin could affect postprandial glycaemia in healthy volunteers and be partially responsible for the glycaemic index of orange juice which is lower than predicted based on its sugar content. Hesperidin lowered glucose transport across differentiated Caco-2/TC7 cell monolayers and inhibited GLUT2 and GLUT5 transporters when specifically expressed in X. laevis oocytes. Hesperidin, however, did not inhibit rat intestinal sucrase activity. These in vitro data suggest that hesperidin could possibly act to slow down the rate of sugar absorption in vivo. While testing orange juice on healthy volunteers, we found that the postprandial glycaemic response was blunted under certain conditions as assessed by the peak blood glucose concentration relative to a control drink containing the constituent sugars, organic acids and vitamin C. In comparison, change in AUC did not reach significance (Fig. 10). These data imply that the hesperidin or other non-nutrient components of orange juice could be acting to slow down the glucose absorption step through partial inhibition of intestinal sugar transport, which would lead to lowered maximum glucose blood glucose concentration but result in no change in the total sugar absorbed, since the absorption can occur along the length of the intestine and would therefore be shifted to a later time.
The solubility of hesperidin is complex, and this can influence results obtained in vitro. Hesperidin is soluble in pure water up to 50 µm ( Reference Tommasini, Calabro and Stancanelli 33 ), although we have found that it is much more soluble, at least transiently for the timescale of an experiment, when dissolved first in DMSO and then introduced into an aqueous milieu. In orange juice, it is present at up to millimolar concentrations, and higher concentrations have been previously used in intervention studies on hesperidin-enriched orange juice( Reference Vallejo, Larrosa and Escudero 34 ). The solubility of hesperidin is also modified when present in the orange juice matrix; and although the exact location and form of hesperidin is not known, it is clearly heterogeneous as some techniques such as centrifugation or filtering remove only a proportion of the hesperidin( Reference Vallejo, Larrosa and Escudero 34 ). In commercially available orange juices, the distribution of hesperidin between ‘soluble’ and ‘insoluble’ fractions was variable depending on processing. After orange juice consumption, hesperidin stays in the small intestine without being digested or modified, until it reaches the colon.
We ascribe the changes in the intervention studies to partial inhibition of intestinal GLUT by hesperidin and not to the inhibition of digestive brush border enzymes such as sucrase. We clearly show that hesperidin does not inhibit rat sucrase activity (an α-glucosidase-type activity), even when present in solution at 1 mm. The aglycone, hesperetin, inhibited α-glucosidase from Saccharomyces cerevisiae with IC50=0·38 (sd 0·05) mm ( Reference Gong, Qin and Zhai 35 ), but this is a yeast enzyme with very little sequence homology to mammalian enzymes, and hence it is not relevant to human or animal nutrition. In addition, hesperetin in the aglycone form is at extremely low levels in orange juice. We have unpublished results (G Williamson, unpublished results) to show that hesperidin does not inhibit human α-amylase activity, and so it is unlikely that hesperidin in orange juice would inhibit the digestion of starch if consumed with a starchy food such as bread.
We have previously shown that polyphenol-rich apple and strawberry extracts( Reference Manzano and Williamson 11 ), a multi-plant supplement( Reference Farrell, Ellam and Forrelli 36 ), a chamomile extract( Reference Villa-Rodriguez, Aydin and Gauer 13 ), and oleuropein from olives( Reference Kerimi, Nyambe-Silavwe and Pyner 12 ) inhibited 14C-glucose transport across the differentiated Caco-2 cell model. The mechanism is due to the inhibition of specific sugar transporters. Here we show that hesperetin was a more potent inhibitor of GLUT2 than hesperidin, which is comparable with the greater effect of quercetin aglycone, but not rutin, on inhibition of GLUT2 expressed in Xenopus oocytes( Reference Song, Kwon and Chen 37 , Reference Kwon, Eck and Chen 38 ). Further the aglycone of naringenin but not the glycoside inhibited glucose uptake in rabbit and rat intestine in vitro ( Reference Li, Che and Lau 10 ). However, it is notable that hesperidin, but not the aglycone hesperetin, inhibited the uptake of fructose by GLUT5 expressed in X. laevis oocytes, and this could account for some of the mild attenuation of fructose transport across Caco-2/TC7 cell monolayers. Hesperetin-7-[2-O-(α-l-rhamnopyranosyl)-β-d-glucopyranoside] (neohesperidin) inhibited the uptake of 3H-glucose (1 mm) into Caco-2 cells by approximately 50 %, but the cells were not on permeable filters and so apical to basolateral transport was not examined. In Na-free conditions, the inhibition of uptake by neohesperidin was abolished, implying that neohesperidin interacted with SGLT1( Reference Johnston, Sharp and Clifford 39 ). Hesperetin also inhibited glucose uptake in breast cancer cells by down-regulation of GLUT1 and inhibited insulin-induced GLUT4 translocation( Reference Yang, Wolfram and Boom 40 ). A related polyphenol, homoeriodictyol, increased glucose uptake in Caco-2 cells via an SGLT-1-meditated pathway( Reference Lieder, Hoi and Holik 41 ). Since only the hesperetin component of hesperidin is absorbed, and not the intact hesperidin itself, the treatment of non-gut cells is not relevant to human nutrition and though hesperidin protected retinal ganglial RGC-5 cells from high-glucose-induced stress( Reference Liu, Liou and Hong 42 ), this is unlikely to occur in vivo.
The main limitation of the study is that the participants and the investigators were not blinded to the interventions, owing to the nature of the food. The study was also not truly randomised, though we think that it is unlikely that a single postprandial intervention would change the response to the next intervention several days later. Identical orange juice was used for the three intervention studies, but it was different to that used for the in vitro studies, and further, the method of analysis of the juices used for the in vitro work was different to that used for the intervention studies. There were no reported side effect or harm, as the treatments were well within the parameters of food as normally consumed. Despite any limitations, we can conclude that, in summary, the presence of hesperidin in orange juice slows down absorption of glucose in the intestine, owing mainly to the effects on the GLUT2 transporter. This is sufficient to blunt the maximum postprandial glucose concentration and increases the time required for total glucose absorption especially when the orange juice is diluted, without significantly modifying the total amount of sugar absorbed in healthy volunteers.
Acknowledgements
The authors thank the Florida Department of Citrus, an executive agency of the Florida government, USA, for funding part of this work. The authors also thank the volunteers and also Mr Ryan Kuipers for help with the human intervention studies.
Planning of research, analysis of data, writing paper, cell transport experiments, analysis of organic acids and sugars of ‘orange juice 2’: A. K. Oocyte experiments: J. S. G. Hesperidin analysis, sucrase assays: S. C. Human intervention studies: J. W. C., J. L. Analysis of ‘orange juice 1’, planning research, provision of materials: P. F. C., R. W. Planning of research, analysis of data, writing paper: G. W.
R. W. and P. F. C. are, or were, employed by the Florida Department of Citrus, an executive agency of Florida tasked with the promotion, protection and regulation of the Florida Citrus industry based in Bartow, Florida. The work reported here was partially funded by the Florida Department of Citrus. G. W. has received funding from Nestlé, and conducted consultancy for Nutrilite, USA, and Suntory, UK. The other authors report no conflict of interest.